A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

NCT06131437 · Completed

Last updated 2026-05-28

This study is testing whether the medication CagriSema helps people with obesity lose weight as effectively as tirzepatide.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 809 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-11 · est. completion 2026-01

Where 46 sites · United States

What this study is testing ClinicalTrials.gov NCT06131437 ↗

Description as written by the study sponsor.

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.

Treatments tested

Cagrilintide Drug

Cagrilintide will be administered subcutaneously.
Semaglutide Drug

Semaglutide will be administered subcutaneously.
Tirzepatide Drug

Tirzepatide will be administered subcutaneously.

Main thing measured	To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06131437 ↗